NAD+ dosage chart
500 mg Vial
NAD+ is dosed at 50 mg–100 mg daily via subcutaneous injection in educational protocols. A 500 mg vial reconstituted with bacteriostatic water yields about 166.7 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → 166.7 mg/mL concentration.
- Typical daily range
- 50–100 mg once daily subcutaneously (gradual titration from lower doses).
- Easy measuring
- At 166.7 mg/mL, 1 unit = 0.01 mL = 1.67 mg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles.
Dosing schedule
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 mg | 30 units (0.30 mL) |
| Week 2 | 75 mg | 45 units (0.45 mL) |
| Weeks 3–8 | 100 mg | 60 units (0.60 mL) |
| Weeks 9–12 | 100 mg | 60 units (0.60 mL) |
| Weeks 13–16 | 100 mg | 60 units (0.60 mL) |
Reconstitution steps
- 1Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
- 2Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- 3Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
- 4Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
- 5The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
- 6Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 7Use within 14 days; inspect before each use for clarity.
Important Notes
Practical considerations for consistency, safety, and optimal results.
- Use new, sterile insulin syringes for each injection; dispose of used needles in a proper sharps container.
- Rotate injection sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to reduce soreness and prevent lipohypertrophy.
- Clean both the vial stopper and injection site with alcohol swabs; allow skin to air‑dry before injecting.
- Inject slowly over 5–10 seconds to minimize tissue irritation; wait a few seconds before withdrawing the needle.
- Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
- If persistent redness or a lump develops at injection sites, apply over‑the‑counter hydrocortisone cream and rotate to a different location.
- Starting at the low end (50 mg) is recommended to assess individual tolerance before escalating dose.
How This Works
NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience.
Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well‑tolerated in humans, with rapid metabolic clearance and no acute toxicity. However, IV administration requires clinical supervision and specialized equipment.
Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy and wellness applications. Compounded NAD+ can be administered SC in small volumes, and SC self‑injection is convenient for ongoing use. Conservative protocols start around 50–100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance and response.
Potential Benefits & Side Effects
Observations from preclinical models and clinical case reports.
- May support cellular energy production and mitochondrial function through replenishment of NAD+ pools.
- Human case reports and pilot studies suggest benefits at 100–300 mg/day ranges for cognitive support and metabolic health.
- High‑dose IV protocols (500–1,500 mg daily for ~10 days) have been used in open‑label studies for substance use disorder, with reports of reduced cravings and improved mood in follow‑ups.
- No severe adverse events have been reported in published NAD+/NADH trials; side effects are generally mild.
- High doses can produce adverse reactions such as insomnia, anxiety, or fatigue if escalated too quickly; gradual titration is advised.
- Mild injection‑site reactions (redness, itching, soreness) may occur with subcutaneous administration; typically resolve with site rotation.
- Some individuals report transient headache or flushing; these effects are generally dose‑dependent.
- Doses exceeding ~200–300 mg/day should generally be reserved for supervised therapeutic use due to potential for metabolic byproduct accumulation.
Lifestyle Factors
Complementary strategies to maximize NAD+ therapy outcomes.
- Nutrition: Consume a balanced diet rich in NAD+ precursors (niacin/vitamin B3, tryptophan) and support nutrients (B‑vitamins, magnesium). Consider foods that support methylation pathways.
- Exercise: Regular physical activity (both resistance training and aerobic exercise) naturally upregulates cellular NAD+ biosynthesis and enhances mitochondrial adaptations.
- Sleep: Prioritize 7–9 hours of quality sleep per night to support cellular repair processes and optimize circadian NAD+ metabolism.
- Stress Management: Chronic stress depletes NAD+ pools through activation of poly(ADP‑ribose) polymerases (PARPs); incorporate stress‑reduction practices like meditation or yoga.
- Avoid Excessive Alcohol: Alcohol metabolism consumes NAD+; moderate or eliminate alcohol intake during NAD+ protocols.
Injection Technique
General subcutaneous injection guidance based on CDC best‑practice resources and clinical literature.
- Wash hands thoroughly with soap and water.
- Clean the vial stopper with an alcohol swab and allow to air‑dry.
- Select injection site (abdomen at least 2 inches from navel, outer thigh, or back of upper arm) and clean with alcohol swab; allow skin to air‑dry completely before injecting.
- Use a fine, short needle such as a 28–31 gauge insulin syringe.
- Needle length of 5/16 to 1/2 inch (8–12 mm) is sufficient to reach subcutaneous tissue in most adults.
- Standard U‑100 insulin syringes (1 mL capacity) are appropriate for the volumes used in this protocol (0.30–0.60 mL per injection).
- Pinch a fold of skin between your thumb and forefinger to isolate subcutaneous tissue.
- Insert the needle at approximately a 45° angle into the pinched subcutaneous layer. (For ultrashort 4 mm needles, a 90° angle without pinching may be used, but for typical 8–12 mm needles, 45° with pinched skin is recommended.)
- Do not aspirate for subcutaneous injections.
- Depress the plunger slowly and steadily to inject the NAD+ solution over 5–10 seconds. Injecting too rapidly may increase irritation.
- Wait a few seconds after full injection before withdrawing the needle at the same angle it was inserted.
- Apply a clean cotton swab or bandage with light pressure to the site; do not rub vigorously.
- Dispose of the used needle/syringe immediately in a proper sharps container.
- Rotate injection sites systematically to prevent soreness, lipohypertrophy, or scar tissue buildup.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. NAD+ is provided for research use only and is not intended for human consumption. Always consult with a qualified healthcare professional before beginning any new supplementation or therapeutic protocol. Individual responses may vary, and proper medical supervision is recommended for NAD+ therapy.
NAD+ dosage FAQs
How much bacteriostatic water do you use to reconstitute NAD+?
Add 3.0 mL bacteriostatic water → 166.7 mg/mL concentration. for a 500 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the NAD+ dosing schedule look like?
Week 1 — 50 mg — 30 units (0.30 mL); Week 2 — 75 mg — 45 units (0.45 mL); Weeks 3–8 — 100 mg — 60 units (0.60 mL); Weeks 9–12 — 100 mg — 60 units (0.60 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for NAD+?
Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation. Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe. Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
How should reconstituted NAD+ be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles..
How many insulin syringe units equal a NAD+ dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is NAD+ approved for human use?
No. NAD+ is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.

